Effect of Gastrectomy and Anastomosis on Diabetes and Hypertension in Early Gastric Cancer Patients

National Cancer Center, Korea159 enrolled

Overview

The purpose of this study is to determine whether the extent of gastrectomy and anastomosis type affect chronic metabolic disease such as diabetes and hypertension in early gastric cancer patients.

Study Type

OBSERVATIONAL

Enrollment

159

Conditions

Early Gastric Cancer

Interventions

gastrectomyPROCEDURE

subtotal gastrectomy with gastroduodenostomy or loop gastrojejunostomy or Roux Y gastrojejunostomy total gastrectomy with Roux Y esophagojejunostomy

Endoscopic submucosal dissectionPROCEDURE

endoscopic submucosal dissection

Eligibility

Sex: ALLMin age: 20 YearsMax age: 80 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Histologically proven primary gastric adenocarcinoma * clinical stage Ia or Ib examined with endoscopy, endoscopic ultrasound, and computed tomography * aged 20-80 year old, * performance status (PS) of 0 or 1 on Eastern Cooperative Oncology Group (ECOG) scale * diagnosed as diabetes or hypertension * patients planning to undergo gastrectomy or endoscopic submucosal dissection * written informed consent Exclusion Criteria: * having high risk for operation such as severe heart disease, severe respiratory disease * pregnant * previous abdominal surgery or radiation therapy * proven more advanced disease than pathological stage II requiring adjuvant chemotherapy

Locations (1)

National Cancer Center

Goyang, Kyeonggi-do, South Korea

Outcomes

Primary Outcomes

Proportion of patients who quit previous medication for diabetes because of improved disease

proportion of patients who quit their previous medication for diabetes because of improved disease after operation among all patients who underwent gastrectomy for early gastric cancer with diabetes.

Time frame: 5 year after operation

Proportion of patients who quit previous medication for hypertension because of improved disease

Proportion of patients who quit previous medication for hypertension because of improved disease among the patients who diagnosed as early gastric cancer and hypertension

Time frame: 5 years after operation

Secondary Outcomes

difference of proportion of patients who quit previous medication for diabetes between patients who underwent subtotal gastrectomy and those who underwent total gastrectomy

Time frame: 5 years after operation

difference of proportion of patients who quit previous medication for diabetes according to anastomosis

difference of proportion of patients who quit previous medication for diabetes among patients who underwent gastroduodenostomy and loop gastrojejunostomy and Roux-Y gastrojejunostomy

Time frame: 5 year after operation

difference of proportion of patients who quit previous medication for hypertension between patients who underwent subtotal gastrectomy and those who underwent total gastrectomy

Time frame: 5 years after operation

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.